Table1_The Comparison of Plasma and Cerebrospinal Fluid R(−)- and S(+)-Flurbiprofen Concentration After Intravenous Injection of Flurbiprofen Axetil in Human Subjects.XLSX
Background: Flurbiprofen axetil is a prodrug that releases the active substance through enzymatic removal of the ester moiety. It is formulated through encapsulation in a lipid microsphere carrier, and widely used to treat perioperative pain. Here, we studied the distribution of R (−)- and S (+)-flurbiprofen in human plasma and cerebrospinal fluid (CSF) after intravenous injection of flurbiprofen axetil.
Methods: A total of 70 adult patients undergoing elective lower limb surgery under spinal anesthesia were given a single intravenous injection of 100-mg flurbiprofen axetil. The patients were randomly assigned to 10 groups for plasma and CSF sampling at 10 time points (5–50 min) after subarachnoid puncture and before actual spinal anesthesia. R (−)- and S (+)-flurbiprofen and CSF/plasma ratio were determined by liquid chromatography–tandem mass spectrometry.
Results: R (−)-flurbiprofen concentration ranged from 2.01 to 10.9 μg/mL in plasma and 1.46–34.4 ng/mL in CSF. S (+)-flurbiprofen concentration ranged from 1.18 to 10.8 μg/mL in plasma and from 2.53 to 47 ng/mL in CSF. In comparison to S (+)-flurbiprofen, R (−)-flurbiprofen concentration was significantly higher in plasma at all time points (p < 0.05) except at 30 or 40 min, and lower in CSF at all time points (p < 0.05) except at 10, 15 and 40 min. Analysis after correcting drug concentration for body mass index also revealed higher plasma and lower CSF R (−)-flurbiprofen concentration. In comparison to S (+)-flurbiprofen, AUC0–50 for R (−)-flurbiprofen was larger in plasma and smaller in CSF (p < 0.05 for both), and accordingly smaller CSF/plasma AUC0–50 ratio (p < 0.05). There was a positive correlation between R (−)-flurbiprofen concentration and S (+)-flurbiprofen concentration in plasma (r = 0.725, p < 0.001) as well as in CSF (r = 0.718, p < 0.001), and a negative correlation between plasma and CSF concentration of S (+)-flurbiprofen (r = −0.250, p = 0.037), but not R (−)-flurbiprofen.
Conclusion: Distribution of R (−)- and S (+)-flurbiprofen in plasma and CSF differed significantly. Penetration of R (−)-flurbiprofen into the CNS was lower than S (+)-flurbiprofen.
History
References
- https://doi.org//10.1371/journal.pone.0010628
- https://doi.org//10.1016/j.pharmthera.2005.02.004
- https://doi.org//10.1097/00000542-200603000-00005
- https://doi.org//10.1016/0006-2952%2888%2990762-9
- https://doi.org//10.1186/1471-2474-10-127
- https://doi.org//10.1016/j.apmr.2011.05.009
- https://doi.org//10.1007/bf00266343
- https://doi.org//10.1016/0024-3205%2894%2900555-9
- https://doi.org//10.1111/j.1365-2125.1994.tb04295.x
- https://doi.org//10.1046/j.1471-4159.2000.0742094.x
- https://doi.org//10.1016/j.asjsur.2017.01.002
- https://doi.org//10.1002/jps.2600770805
- https://doi.org//10.1111/j.1365-2125.1992.tb04054.x
- https://doi.org//10.1111/j.1365-2125.2010.03720.x
- https://doi.org//10.1007/s00228-003-0574-6
- https://doi.org//10.1016/0014-2999%2894%2990247-x
- https://doi.org//10.2165/00003088-200645070-00008
- https://doi.org//10.1055/s-0031-1300446
- https://doi.org//10.1038/sj.clpt.6100304
- https://doi.org//10.1136/rapm-2019-100700
- https://doi.org//10.1016/0006-2952%2891%2990039-8
- https://doi.org//10.1016/0169-409X%2895%2900123-O
- https://doi.org//10.1016/j.pbb.2008.06.008
- https://doi.org//10.1038/35068566
- https://doi.org//10.3390/molecules180910747
- https://doi.org//10.1002/ddr.21314
- https://doi.org//10.1096/fj.00-0130fje10.1096/fasebj.15.1.2
- https://doi.org//10.2174/138920009789895480
- https://doi.org//10.1002/brb3.1290
- https://doi.org//10.11669/cpj.2013.13.014
- https://doi.org//10.5414/CP203092
- https://doi.org//10.2147/JPR.S176475
- https://doi.org//10.1111/j.1365-2125.2007.02846.x
CC BY 4.0